Standard dose rifampicin — Competitive Intelligence Brief

Standard dose rifampicin (Standard dose rifampicin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial RNA polymerase inhibitor. Area: Infectious Diseases.

phase 3 Bacterial RNA polymerase inhibitor beta subunit of bacterial RNA polymerase Infectious Diseases Small molecule

Target snapshot

Standard dose rifampicin (Standard dose rifampicin) — Radboud University Medical Center. Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard dose rifampicin TARGET	Standard dose rifampicin	Radboud University Medical Center	phase 3	Bacterial RNA polymerase inhibitor	beta subunit of bacterial RNA polymerase
PAR-101/OPT-80	PAR-101/OPT-80	Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Non-systemic antibiotic; bacterial RNA polymerase inhibitor	Bacterial RNA polymerase (C. difficile)
Rifampin containing regimen	Rifampin containing regimen	Nantes University Hospital	phase 3	Bacterial RNA polymerase inhibitor	bacterial RNA polymerase beta subunit
Placebo matched to Rifampin	Placebo matched to Rifampin	Hamilton Health Sciences Corporation	phase 3	Bacterial RNA polymerase inhibitor	Bacterial RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial RNA polymerase inhibitor class)

1. Hamilton Health Sciences Corporation · 1 drug in this class
2. Nantes University Hospital · 1 drug in this class
3. Radboud University Medical Center · 1 drug in this class